Skip to main content

Advertisement

SpringerLink
Log in

Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

To examine the clinicopathologic and immunohistochemical features of a group of newly defined low-grade oncocytic renal tumors (LOT) that have the “CD117 negative/cytokeratin (CK)7 positive” immunoprofile. We have queried our hospital database and found 4456 consecutive renal tumors between 2016 and 2019. Among these renal tumors, eight (8) cases meet the morphologic and immunohistochemical characterization for low-grade oncocytic renal tumor (LOT). The eight (8) patients’ mean age is 56.6 years (range 39–70 years old), and the male to female ratio is 1:1. Macroscopically, these LOTs generally present with tan-brown and solid cut surfaces and demonstrate similar solid, compact nested growth pattern microscopically. Tumor cells exhibit oncocytic cytoplasm and uniformly rounded to oval nuclei. There are areas of edematous stroma containing dispersed single or small clustered tumor cells. All tumors are negative for CD117 and positive for CK7. Uniform reactivity is also found for BerEP4, cyclin D1, and SDHB. Besides, CD10, vimentin, and AMACR are either negative or only focally positive. All of the tumors are negative for CA9 and TFE. The Ki-67 index is less than 5% in the seven (7) internal cases. Seven (7) of the eight (8) patients who are available for follow-up are alive and without disease recurrence (mean follow-up period of 21.6 months, ranging from 6 to 43 months). We described a group of low-grade oncocytic renal tumors identified retrospectively in a large tertiary cancer center, which was probably the first report originated from China or even Asia in the English literature so far. These tumors demonstrated eosinophilic cytoplasm and low-grade appearing nuclei with a “CD117 negative/CK7 positive” immunoprofile. The incidence rate was about 3.7% of the oncocytic renal tumors and 0.18% of all the renal tumors that were received in our lab during the four-year period. It is necessary to separate this group of tumors by its characteristic morphologic and immunophenotypic features.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Moch H, Humphrey PA, Ulbright TM, Reuter V (2016) WHO classification of tumours of the urinary system and male genital organs. International Agency for Research on Cancer, Lyon, France

    Google Scholar 

  2. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P, ISUP Renal Tumor Panel (2013) The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469–1489

    Article  Google Scholar 

  3. Williamson SR, Gadde R, Trpkov K, Hirsch MS, Srigley JR, Reuter VE, Cheng L, Kunju LP, Barod R, Rogers CG, Delahunt B, Hes O, Eble JN, Zhou M, McKenney JK, Martignoni G, Fleming S, Grignon DJ, Moch H, Gupta NS (2017) Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Hum. Pathol. 63:149–156

    Article  Google Scholar 

  4. Iczkowski KA, Czaja RC (2019) Eosinophilic kidney tumors: old and new. Arch Pathol Lab Med. 143(12):1455–1463

    Article  CAS  Google Scholar 

  5. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R (2015) National comprehensive cancer network, Kidney cancer, version 3.2015. J Natl Compr Canc Netw 13:151–159

    Article  Google Scholar 

  6. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67:913–924

    Article  Google Scholar 

  7. Stewart SB, Thompson RH, Psutka SP, Cheville JC, Lohse CM, Boorjian SA, Leibovich BC (2014) Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. J Clin Oncol 32:4059–4065

    Article  Google Scholar 

  8. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Herrell SD, Hilton S, Jonasch E, Lin DW, Reuter VE, Chang SS (2013) Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 190:407–416

    Article  Google Scholar 

  9. Trpkov K, Hes O (2019) New and emerging renal entities: a perspective post-WHO 2016 classification. Histopathology. 74(1):31–59

    Article  Google Scholar 

  10. Siadat F, Trpkov K (2020) ESC, ALK, HOT and LOT: three letter acronyms of emerging renal entities knocking on the door of the WHO classification. Cancers (Basel) 12(1):168. Published 2020 January 9th. https://doi.org/10.3390/cancers12010168

    Article  Google Scholar 

  11. Trpkov K, Williamson SR, Gao Y, Martinek P, Cheng L, Sangoi AR, Yilmaz A, Wang C, San Miguel Fraile P, Perez Montiel DM, Bulimbasić S, Rogala J, Hes O (2019) Low-grade oncocytic tumor of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology. 75(2):174–184

    Article  Google Scholar 

  12. Trpkov K, Yilmaz A, Uzer D, Dishongh KM, Quick CM, Bismar TA, Gokden N (2010) Renal oncocytoma revisited: a clinicopathological study of 109 cases with emphasis on problematic diagnostic features. Histopathology. 57(6):893–906

    Article  Google Scholar 

  13. Abrahams NA, MacLennan GT, Khoury JD et al (2004) Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. Histopathology. 45:593–602

    Article  CAS  Google Scholar 

  14. Hes O, Brunelli M, Michal M, Cossu Rocca P, Hora M, Chilosi M, Mina M, Boudova L, Menestrina F, Martignoni G (2006) Oncocytic papillary renal cell carcinoma: a clinicopathologic, immunohistochemical, ultrastructural, and interphase cytogenetic study of 12 cases. Ann Diagn Pathol. 10(3):133–139

    Article  Google Scholar 

  15. Amin MB, Gupta R, Hes O et al (2009) Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol. 33(3):393–400

    Article  Google Scholar 

  16. Ellis CL, Eble JN, Subhawong AP, Martignoni G, Zhong M, Ladanyi M, Epstein JI, Netto GJ, Argani P (2014) Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Mod Pathol. 27(6):875–886

    Article  CAS  Google Scholar 

  17. Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, Agaimy A, Amin MB, Argani P, Chen YB, Cheng L, Colecchia M, Compérat E, Werneck da Cunha I, Epstein JI, Gill AJ, Hes O, Hirsch MS, Jochum W, Kunju LP, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Nesi G, Osunkoya AO, Picken MM, Rao P, Reuter VE, de Oliveira Salles PG, Schultz L, Tickoo SK, Tomlins SA, Trpkov K, Amin MB (2018) Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 42(3):279–292

    Article  Google Scholar 

  18. Gill AJ, Hes O, Papathomas T, Šedivcová M, Tan PH, Agaimy A, Andresen PA, Kedziora A, Clarkson A, Toon CW, Sioson L, Watson N, Chou A, Paik J, Clifton-Bligh RJ, Robinson BG, Benn DE, Hills K, Maclean F, Niemeijer ND, Vlatkovic L, Hartmann A, Corssmit EPM, van Leenders GJLH, Przybycin C, McKenney JK, Magi-Galluzzi C, Yilmaz A, Yu D, Nicoll KD, Yong JL, Sibony M, Yakirevich E, Fleming S, Chow CW, Miettinen M, Michal M, Trpkov K (2014) Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 38(12):1588–1602

    Article  Google Scholar 

  19. Klein MJ, Valensi QJ (1976) Proximal tubular adenomas of kidney with so-called oncocytic features. A clinicopathologic study of 13 cases of a rarely reported neoplasm. Cancer 38:906–914

    Article  CAS  Google Scholar 

  20. Kravtsov O, Gupta S, Cheville J, Hernandez L, Jimenez R (2020) Low-grade oncocytic tumor of kidney (CK7-positive, CD117-negative): a single institutional experience with incidence and clinicopathological characteristics. Modern Pathology 33:917–918 Abstract number 950

    Google Scholar 

  21. Thoenes W, Storkel S, Rumpelt HJ (1985) Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 48:207–217

    Article  CAS  Google Scholar 

  22. Kuroda N, Tanaka A, Yamaguchi T, Kasahara K, Naruse K, Yamada Y, Hatanaka K, Shinohara N, Nagashima Y, Mikami S, Oya M, Hamashima T, Michal M, Hes O (2013) Chromophobe renal cell carcinoma, oncocytic variant: a proposal of a new variant giving a critical diagnostic pitfall in diagnosing renal oncocytic tumors. Med Mol Morphol. 46(1):49–55

    Article  Google Scholar 

  23. Ng KL, Rajandram R, Morais C, Yap NY, Samaratunga H, Gobe GC, Wood ST (2014) Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem? J Clin Pathol. 67(2):97–104

    Article  Google Scholar 

  24. Morini A, Drossart T, Timsit M, Mejean A, Thibault C, Gimenez-Roqueplo A, Favier F, Burnichon N, Verkarre V. Immunohistochemical evaluation of the mTOR pathway of genetically characterized chromophobe renal cell carcinomas: a pilot study of 20 cases. Modern Pathology. volume 33, pages 940–941(2020). Abstract number 976

  25. Delongchamps NB, Galmmiche L, Eiss D, et al. Hybrid tumor “oncocytoma-chromophobe renal cell carcinoma” of the kidney: a report of seven sporadic cases. BJU Int. 2009;103(10):1381–1384, Hybrid tumour ‘oncocytoma-chromophobe renal cell carcinoma’ of the kidney: a report of seven sporadic cases.

  26. Petersson F, Gatalica Z, Grossmann P, Perez Montiel MD, Alvarado Cabrero I, Bulimbasic S, Swatek A, Straka L, Tichy T, Hora M, Kuroda N, Legendre B, Michal M, Hes O (2010) Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch 456:355–365

    Article  Google Scholar 

  27. Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CWB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K (2019) Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 32(11):1698–1707

    Article  CAS  Google Scholar 

  28. Mikami S, Kuroda N, Nagashima Y, Ohe C, Hayashi H, Mizuno R, Oya M, Kameyama K (2019) Classification of solid renal tumor with oncocytic/eosinophilic cytoplasm: is hybrid oncocytic/chromophobe renal tumor a subtype of oncocytoma, chromophobe renal cell carcinoma, or a distinct tumor entity? Ann Transl Med. 7(Suppl 8):S350

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Tianjin Medical University Cancer Institute and Hospital and National Clinical Research Center for Cancer.

Funding

This work was funded by the Project the National Natural Science Foundation of China (No. 81700103), the Tianjin Municipal Health Bureau Science and Technology Foundation (Grant No.16KG125), and the Project of Tumor Translational Medicine Seed Fund of Tianjin Medical University Cancer Institute and Hospital (No. 1905).

Author information

Author notes

  1. Qianru Guo and Ning Liu contributed equally to this work.

Authors and Affiliations

  1. Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, 300060, People’s Republic of China

    Qianru Guo, Yuhong Guo, Bo Yang, Zi Cao, Yalei Wang, Yong Wang, Wenshuai Zhang, Qiujuan Huang, Wei Zhao, Changxu Liu, Tongyuan Qu, Lingmei Li, Lu Cao, Danyang Ren, Bin Meng, Lisha Qi & Wenfeng Cao

  2. Tianjin Baodi Hospital/Baodi Clinical College of Tianjin Medical University, Tianjin, People’s Republic of China

    Ning Liu

  3. McMaster University, Hamilton, Ontario, Canada

    Frank Wang

  4. QEII Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada

    Cheng Wang

Authors
  1. Qianru Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ning Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuhong Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bo Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zi Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yalei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wenshuai Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Qiujuan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wei Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Changxu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tongyuan Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Lingmei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Lu Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Danyang Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Bin Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Lisha Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Cheng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Wenfeng Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All the authors met the criteria listed in the ICMJE recommendations for the qualification of authorship.

Qianru Guo, Ning Liu, Frank Wang, Bo Yang, Lisha Qi, Cheng Wang, and Wenfeng Cao designed the research study.

Qianru Guo, Ning Liu, Frank Wang, Bo Yang, Yong Wang, Wenshuai Zhang, Qiujuan Huang, Wei Zhao, Changxu Liu, Tongyuan Qu, Lingmei Li, Yanan Gao, Lu Cao, Danyang Ren, Bin Meng, Lisha Qi, Cheng Wang, and Wenfeng Cao performed the research.

Yuhong Guo, Zi Cao, and Yalei Wang contributed essential reagents or tools.

Qianru Guo, Ning Liu, Frank Wang, Wenshuai Zhang, Cheng Wang, and Wenfeng Cao analyzed the data.

Qianru Guo, Ning Liu, Frank Wang, Cheng Wang, and Wenfeng Cao wrote the paper.

Corresponding authors

Correspondence to Cheng Wang or Wenfeng Cao.

Ethics declarations

This study protocol was approved by the Research Ethics Committee of Tianjin Medical University Cancer Institute & Hospital (bc2016022).

Conflict of interest

The authors declare that they have no financial or other conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Quality in Pathology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, Q., Liu, N., Wang, F. et al. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China. Virchows Arch 478, 449–458 (2021). https://doi.org/10.1007/s00428-020-02927-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-020-02927-0

Keywords

Search

Navigation